Richard Pearson

Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy

Jian Kang, Natalie Brajanovski, Keefe T Chan, Jiachen Xuan, Richard B Pearson, Elaine Sanij

Journal article  |  2021  |  SIGNAL TRANSDUCTION AND TARGETED THERAPY

Ribosome biogenesis and protein synthesis are fundamental rate-limiting steps for cell growth and proliferation. The ribosomal pro..

CX-5461 sensitises DNA damage repair proficient castrate-resistant prostate cancer to PARP inhibition.

Mitchell G Lawrence, Laura H Porter, Nicholas Choo, David Pook, Jeremy P Grummet, Carmel J Pezaro, Shahneen Sandhu, Susanne Ramm, Jennii Luu, Andrew Bakshi, David L Goode, Elaine Sanij, Richard B Pearson, Ross D Hannan, Kaylene J Simpson, Renea A Taylor, Gail P Risbridger, Luc Furic

Journal article  |  2021  |  Mol Cancer Ther

Monotherapy with poly (ADP-ribose) polymerase (PARP) inhibitors is effective for the subset of castrate-resistant prostate cancer ..

Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death

Ana Domostegui, Suresh Peddigari, Carol A Mercer, Flavia Iannizzotto, Marta L Rodriguez, Marta Garcia-Cajide, Virginia Amador, Sarah T Diepstraten, Gemma L Kelly, Ramon Salazar, Sara C Kozma, Eric P Kusnadi, Jian Kang, Antonio Gentilella, Richard B Pearson, George Thomas, Joffrey Pelletier

Journal article  |  2021  |  BLOOD

MYC-driven B-cell lymphomas are addicted to increased levels of ribosome biogenesis (RiBi), offering the potential for therapeutic..

The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer

Shunfei Yan, Jiachen Xuan, Natalie Brajanovski, Madeleine RC Tancock, Piyush B Madhamshettiwar, Kaylene J Simpson, Sarah Ellis, Jian Kang, Carleen Cullinane, Karen E Sheppard, Katherine M Hannan, Ross D Hannan, Elaine Sanij, Richard B Pearson, Keefe T Chan

Journal article  |  2020  |  BRITISH JOURNAL OF CANCER

BACKGROUND: Intrinsic and acquired drug resistance represent fundamental barriers to the cure of high-grade serous ovarian carcino..

Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis

Eric P Kusnadi, Anna S Trigos, Carleen Cullinane, David L Goode, Ola Larsson, Jennifer R Devlin, Keefe T Chan, David P De Souza, Malcolm J McConville, Grant A McArthur, George Thomas, Elaine Sanij, Gretchen Poortinga, Ross D Hannan, Katherine M Hannan, Jian Kang, Richard B Pearson

Journal article  |  2020  |  EMBO JOURNAL

Elevated ribosome biogenesis in oncogene-driven cancers is commonly targeted by DNA-damaging cytotoxic drugs. Our previous first-i..

CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer

Jiachen Xuan, Richard B Pearson, Elaine Sanij

Journal article  |  2020  |  MOLECULAR & CELLULAR ONCOLOGY

Acquired drug resistance leads to poor clinical outcome in high grade serous ovarian cancer (HGSOC). We have demonstrated the effi..

Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC-Driven Cancer Progression

Jixuan Gao, MoonSun Jung, Chelsea Mayoh, Pooja Venkat, Katherine M Hannan, Jamie Fletcher, Alvin Kamili, Andrew J Gifford, Eric P Kusnadi, Richard B Pearson, Ross D Hannan, Michelle Haber, Murray D Norris, Klaartje Somers, Michelle J Henderson

Journal article  |  2020  |  CANCER RESEARCH

The ability of the N-MYC transcription factor to drive cancer progression is well demonstrated in neuroblastoma, the most common e..

rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461

Jinbae Son, Katherine M Hannan, Gretchen Poortinga, Nadine Hein, Donald P Cameron, Austen RD Ganley, Karen E Sheppard, Richard B Pearson, Ross D Hannan, Elaine Sanij

Journal article  |  2020  |  FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY

Hyperactivation of RNA polymerase I (Pol I) transcription of ribosomal RNA (rRNA) genes (rDNA) is a key determinant of growth and ..

Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade serous ovarian cancer.

Elaine Sanij, Katherine Hannan, Jiachen Xuan, Shunfei Yan, Jessica A Ahern, Anna S Trigos, Natalie Brajanovski, Jinbae Son, Keefe T Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J Wakefield, Sarah Ellis, Carleen Cullinane, Gretchen Poortinga, Kum Kum Khanna, Linda Mileshkin, Grant A McArthur, John Soong, Els M Berns, et al.

Conference Proceedings  |  2020  |  CLINICAL CANCER RESEARCH

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer

Elaine Sanij, Katherine M Hannan, Jiachen Xuan, Shunfei Yan, Jessica E Ahern, Anna S Trigos, Natalie Brajanovski, Jinbae Son, Keefe T Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J Wakefield, Daniel Frank, Sarah Ellis, Carleen Cullinane, Jian Kang, Gretchen Poortinga, Purba Nag, Andrew J Deans, Kum Kum Khanna, et al.

Journal article  |  2020  |  NATURE COMMUNICATIONS

Acquired resistance to PARP inhibitors (PARPi) is a major challenge for the clinical management of high grade serous ovarian cance..